AUTHOR INSIGHT, COMMUNITY NEWS & EVENTS BY ONCOTARGET:
- Oncotarget | Mivavotinib for Relapsed/Refractory B-cell Lymphoma (Updated)PRESS RELEASE: On January 26, 2023, a new research paper was published in Oncotarget, entitled, “Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659).”
- Oncotarget | Intraventricular Immunovirotherapy; A Translational Step ForwardPRESS RELEASE: On January 12, 2023, a new research perspective was published in Oncotarget, entitled, “Intraventricular immunovirotherapy; a translational step forward.”
- Oncotarget | The Chromatographic Constitution of Andiroba Oil and its Healing Effects…PRESS RELEASE: On January 12, 2023, Oncotarget published a new research paper: “The chromatographic constitution of andiroba oil and its healing effects, compared to the LLLT outcomes, in oral mucositis induced in golden Syrian hamsters: a new treatment option.”
Visit this page to hear from the distinguished network of authors who continue to publish their research with Oncotarget—an open access biomedical journal dedicated to publishing the latest oncology-focused, peer-reviewed research papers. Here, readers will also find information about community news and events sponsored by Oncotarget.
For the latest summaries of new and trending Oncotarget papers,visit Oncotarget.org or ImpactJournals.com. Impact Journals is Oncotarget’s academic publisher. Read about our rigorous Scientific Integrity Process.
On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed.
Oncotarget is published by Impact Journals of Orchard Park, New York. Impact Journals meets the standards established Wellcome Trust Publisher Requirements and is included on the Wellcome Trust List of Compliant Publishers.
Oncotarget is proud to have multiple Nobel Prize winning members on its editorial board, in addition to editors who have won the Lasker Prize and other prestigious recognitions. The open-access model employed by Oncotarget allows for free dissemination of thoroughly vetted peer-reviewed research material to the general public, leading to bigger and more frequent scientific breakthroughs. Because of Oncotarget’s uniquely varied scope, the journal has consistently published research on a wide range of subject areas, allowing readers to access an unparalleled diversity of knowledge in only one publication.
The founding editors of Oncotarget are Dr. Blagosklonny and Dr. Gudkov. Dr. Blagosklonny is well-known for his research in the field of aging, having published numerous papers on the subject. Dr. Blagosklonny is credited for advancing groundbreaking research of the drug Rapamycin, an anti-aging medicine that has shown to slow down the aging process. Having been featured in numerous publications on aging including a Scientific American article titled “A New Path to Longevity,” Dr. Blagosklonny continues to provide meaningfully important contributions to the scientific community.
To get in touch with Oncotarget, please visit our website. The journal’s ISSN is 1949-2553 and is indexed and/or archived in PubMed, Scopus, PMC, and the Chan Zuckerberg Meta initiative.